Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BLAs More Appealing As 'Transition' NDAs, ANDAs Set To Lose Exclusivity

Executive Summary

Certain protein products approved under FD&C Act before March 23, 2020 would lose their remaining non- orphan exclusivity, and would not qualify for 12-year biologic exclusivity.


Related Content

Biologics Transition Plan From US FDA Will Consider Therapeutic Equivalence Ratings
USP Backs Down From Biologic Monograph Naming Plan Amid US FDA Objections
Generic Labeling Rule Dies In Latest Reg Agenda, But Electronic Labeling Is Reborn
Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms
Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts